ECLAI is a project initiated by CIBERONC as part of the international ERA PerMed JTC2021 call and supported by the Spanish Association Against Cancer. This project aims to personalise the clinical management of advanced endometrial cancer (EC) by combining liquid biopsy, genomics and artificial intelligence, with the ultimate goal of improving the life expectancy and quality of life of patients with EC who currently have limited clinical options. It is led by Dr. Gema Moreno-Bueno, CIBERONC IP at the UAM and MD Anderson Foundation, and Dr. Laura Muinelo, a CIBERONC researcher in the group of Rafael Lopez at the U. de Santiago Hospital. It is supported by international institutions in Poland (Medical University of Lubin), Norway (University of Bergen) and Estonia (Centre on Health Technologies).